미숙아망막병증 진단과 치료의 최신 지견

• 영문명: Update on Diagnosis and Treatment of Retinopathy of Prematurity
• 발행기관: 대한검안학회
• 저자명: 허 환(Hwan Heo)
• 간행물 정보: 『Annals of optometry and contact lens』Vol.17 No.4, 83~88쪽, 전체 6쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2018.12.30

영문 초록

Retinopathy of prematurity is still the leading cause of blindness in children. It is on the rise due to the development of postnatal care technology in developing and developed countries. However, due to the lack of experts, appropriate diagnosis and treatment are often not available. Therefore, it is necessary to develop technologies such as telemedicine and diagnostic automation technology for retinopathy of prematurity. Experts should know that the difference of timing and nature of recurrence between intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection and laser treatment. And, after verifying safety dose and systemic complication, guidelines for safe use of intravitreal anti-VEGF injection should be developed.

목차

서 론

본 론

결 론

REFERENCES

키워드

Bevacizumab Ranibizumab Retinopathy of prematurity Telemedicine